{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003998091,0.0003213703,0.0009271504,0.0001332361,0.00008278635,0.000004482862,0.0001051048,0.0001293841,0.0002158931],"category_scores_gemma":[0.00004022072,0.0002076267,0.0001704349,0.0002595076,0.0001757481,0.00007492522,0.00001206857,0.0002999002,0.000005924683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004986499,"about_ca_system_score_gemma":0.0004259961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007846477,"about_ca_topic_score_gemma":0.00002442158,"domain_scores_codex":[0.9980205,0.0002524001,0.0005392663,0.0004680272,0.0002810715,0.0004386991],"domain_scores_gemma":[0.9987644,0.0003986682,0.0001524001,0.0002809569,0.00007590589,0.0003276781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007553964,0.001764819,0.0004855418,0.0002227579,0.00004795294,0.00009312064,0.0002578667,6.909162e-7,0.0002610749,0.0001598066,0.0002498727,0.9957011],"study_design_scores_gemma":[0.008948921,0.01030371,0.006513787,0.0002266696,0.000338051,0.0002296168,0.00008302756,0.00009129778,0.0008487034,0.001223553,0.9710056,0.0001871046],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04824978,0.9327261,0.0004165066,0.01483328,0.0004760323,0.002073356,0.000009851354,0.00004859193,0.001166447],"genre_scores_gemma":[0.2354593,0.7554459,0.002037865,0.005857137,0.0005207596,0.0004963389,0.00006630509,0.00002273411,0.00009362937],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.995514,"threshold_uncertainty_score":0.846677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03495072061428077,"score_gpt":0.3814300607698013,"score_spread":0.3464793401555206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}